Andere Sprachen XOMA Corporation Nasdaq

Aktien

A3CLTK

US98419J3059

XOMAP

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:00 07.06.2024			% 5 Tage	% 1. Jan.
25 ^USD	-0,31 %		-1,22 %	-1,61 %

09.05.	XOMA Corporation meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
30.04.	Die XOMA Corporation (NasdaqGM:XOMA) hat die Übernahme von drei First-in-Category Assets von Daré Bioscience, Inc. (NasdaqCM:DARE) für 22 Millionen Dollar abgeschlossen.	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ	14.05.
Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M	09.05.
Xoma: Q1 Earnings Snapshot	09.05.
XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	09.05.
XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities	09.05.
XOMA : 2024 Letter to Shareholders	09.05.
XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%	30.04.
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	30.04.
XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One’s OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)	25.04.
XOMA : Acquisition/Asset Disposal - Form 8-K	03.04.
XOMA Corporation Announces Closing of Tender Offer	03.04.
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	03.04.
XOMA Declares Quarterly Preferred Stock Dividends	21.03.
XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.	19.03.
Xoma: Q4 Earnings Snapshot	08.03.
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	08.03.
XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value	08.03.
XOMA to Present at Upcoming Investor Conferences in March	28.02.
XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash per Share plus a Contingent Value Right	19.02.
Shareholder Alert: Ademi LLP investigates whether Kinnate Biopharma Inc. has obtained a Fair Price in its transaction with XOMA	16.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen XOMA Corporation Nasdaq

Aktien

A3CLTK

US98419J3059

XOMAP

Andere Sprachen

Filter